The American Journal of Surgery
Volume 194, Issue 5 , Pages 628-632 , November 2007

Keyhole limpet hemocyanin: an effective adjunct against melanoma in vivo

Presented at the 31st Annual Surgical Symposium of the Association of VA Surgeons, Little Rock, AR, May 10–12, 2007

Received 23 May 2007 ,Revised 7 August 2007

References 

  1. Jemal A, Siegal R, Ward E, et al. Cancer Statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  2. McGillis ST, Fein H. Topical treatment strategies for non-melanoma skin cancer and precursor lesions. Semin Cutan Med Surg. 2004;23:174–183
  3. Villa AM, Berman B. Immunomodulators for skin cancer. J Drugs Dermatol. 2004;3:533–539
  4. Harris JR, Markl J. Keyhole limpet hemocyanin: Molecular structure of a potent marine immunoactivator (A review). Eur Urol. 2000;37(suppl 3):24–33
  5. Harris JR, Markl J. Keyhole limpet hemocyanin (KLH): a biomedical review. Micron. 1999;30:597–623
  6. Olsson CA, Chute R, Rao CN. Immunologic reduction of bladder cancer recurrence rate. J Urol. 1974;111:173–176
  7. Riggs DR, Tarry WF, DeHaven JI, et al. Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy. J Urol. 1992;147:212–214
  8. Jurincic CD, Engelmann U, Gasch J, et al. Immunotherapy in bladder cancer with keyhole-limpet hemocyanin: a randomized study. J Urol. 1988;139:723–726
  9. Jurincic-Winkler CD, Metz KA, Beuth J, et al. Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study. Eur Urol. 2000;37(suppl 3):45–49
  10. Lamm DL, DeHaven JI, Riggs DR. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur Urol. 2000;37(suppl 3):41–44
  11. Riggs D, Jackson B, Vona-Davis L, et al. In vitro anticancer effects of a novel immunostimulant: keyhole limpet hemocyanin. J Surg Res. 2002;108:279–284
  12. Somasundar P, Riggs DR, Jackson BJ, et al. Inhibition of melanoma growth by hemocyanin occurs via early apoptotic pathways. Am J Surg. 2005;190:713–716
  13. Riggs DR, Jackson BJ, Vona-Davis L, et al. In vitro effects of keyhole limpet hemocyanin in breast and pancreatic cancer in regards to cell growth, cytokine production, and apoptosis. Am J Surg. 2005;189:680–684
  14. McFadden DW, Riggs DR, Jackson BJ, et al. Keyhole limpet hemocyanin, a novel immune stimulant with promising anticancer activity in Barrett’s esophageal adenocarcinoma. Am J Surg. 2003;186:552–555
  15. Vona-Davis L, Vincent T, Zulfiqar S, et al. Proteomic analysis of SEG-1 human Barrett’s-associated esophageal adenocarcinoma cells treated with keyhole limpet hemocyanin. J Gastrointest Surg. 2004;8:1018–1023
  16. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol. 1996;14:7–17
  17. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–2116
  18. McFadden DW, Riggs DR, Jackson BJ, et al. Keyhole limpet hemocyanin potentiates standard immunotherapy for melanoma. Am J Surg. 2007;193:284–287
  19. Ludbrook J. Multiple comparison procedures updated. Clin Exp Pharmacol Physiol. 1998;25:1032–1037
  20. Dixon WJ, Massey FJ. Introduction to Statistical Analysis. 4th ed.. New York: McGraw-Hill; 1983;
  21. Kirkwood JM, Ibrahim J, Lawson DH, et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group phase II trial E2696. J Clin Oncol. 2001;19:1430–1436
  22. Eggermont AM, Suciu S, Mackie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomized controlled trial. Lancet. 2005;366:1189–1196
  23. Rizvi I, Riggs DR, Jackson BJ, et al. Inositol hexaphosphate (IP6) inhibits cellular proliferation in melanoma. J Surg Res. 2006;133:3–6

PII: S0002-9610(07)00636-8

doi: 10.1016/j.amjsurg.2007.08.005

The American Journal of Surgery
Volume 194, Issue 5 , Pages 628-632 , November 2007

Article Tools

* Image Usage & Resolution